BioStem Technologies reported $6.1 million in revenue for Q1 2026, driven mainly by hospital sales of its Neox® and Clarix® products. The company is integrating BioTissue assets, expanding its salesforce, and focusing on hospital markets to drive growth. Despite a net loss of $8.8 million, BioStem is progressing toward a Nasdaq uplisting with completed audited financials for 2024 and 2025. It expects full-year 2026 revenue between $25 million and $29 million, aiming for growth in both hospital and physician office markets in the second half of the year.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
